Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis.
- Mechanism
- Curator reviewed · 1 reference
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.
- Primary indication
- Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy.Curator reviewed · 3 structured indications
- Formula / weight
- 151500.0 Da (range)
- First approval
- Canada, 2019 · United States, 2017
- Also known as
- hP67.6-Calicheamicin
- Code names
- CDP-771 · CMA-676 · WAY-CMA-676
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Gemtuzumab ozogamicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account